415 related articles for article (PubMed ID: 18650500)
21. Revisiting the rosiglitazone story--lessons learned.
Rosen CJ
N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
[No Abstract] [Full Text] [Related]
22. [The true place of glitazones in the treatment of diabetes: after the PROactive study].
Lindberg M; Jørgensen PH; Kampmann JP
Ugeskr Laeger; 2006 Jun; 168(25):2477-9; author reply 2479-80. PubMed ID: 16824389
[No Abstract] [Full Text] [Related]
23. Pioglitazone: the future.
Brunetti P
Int J Clin Pract Suppl; 2001 Sep; (121):36. PubMed ID: 11594244
[No Abstract] [Full Text] [Related]
24. [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
Olsson AG
Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2454-5. PubMed ID: 17002160
[No Abstract] [Full Text] [Related]
25. Diabetes drug woes spell trouble for the entire drug family.
Wadman M
Nat Med; 2010 Jun; 16(6):614. PubMed ID: 20526294
[No Abstract] [Full Text] [Related]
26. [Glitazones in type 2 diabetes--documented risks, uncertain benefits].
Håkansson J
Lakartidningen; 2007 Oct 24-30; 104(43):3198-200. PubMed ID: 18018937
[No Abstract] [Full Text] [Related]
27. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
28. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
29. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
Odom J; Williamson B; Carter L
Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
[No Abstract] [Full Text] [Related]
30. Pioglitazone/glimepiride (Duetact) for diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
[No Abstract] [Full Text] [Related]
31. Pioglitazone + glimepiride: a combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
[No Abstract] [Full Text] [Related]
32. [Glitazones critically evaluated].
Schernthaner G
Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
[No Abstract] [Full Text] [Related]
33. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli A; Formoso G
Diabetes Obes Metab; 2013 Nov; 15(11):967-77. PubMed ID: 23522285
[TBL] [Abstract][Full Text] [Related]
34. Letter: Iatrogenic lipomatosis: a rare manifestation of treatment with a peroxisome proliferator-activated receptor gamma agonist.
Femia A; Klein PA
Dermatol Online J; 2010 Apr; 16(4):15. PubMed ID: 20409422
[TBL] [Abstract][Full Text] [Related]
35. Rosiglitazone.
Simon D
Prim Care Diabetes; 2009 May; 3(2):123-4. PubMed ID: 19482530
[No Abstract] [Full Text] [Related]
36. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
[TBL] [Abstract][Full Text] [Related]
37. The rosiglitazone controversy: the Indian perspective.
Mohan V; Joshi SR
J Assoc Physicians India; 2007 Jul; 55():477-80. PubMed ID: 17907495
[No Abstract] [Full Text] [Related]
38. The PROactive study: some answers, many questions.
Yki-Järvinen H
Lancet; 2005 Oct; 366(9493):1241-2. PubMed ID: 16214581
[No Abstract] [Full Text] [Related]
39. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
Polonsky T; Mazzone T; Davidson M
Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
[TBL] [Abstract][Full Text] [Related]
40. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
